Alerts will be sent to your verified email
Verify EmailSENORES
Senores Pharmaceutic
|
Ajanta Pharma
|
Alembic Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
53.0 . | 74.0 . | 263.0 . |
Number of ANDA's Approved By USFDA
|
24.0 . | 53.0 . | 219.0 . |
Number of ANDA's Approved
|
n/a | n/a | n/a |
R&D as a % of Total Sales
|
10.71 % | 5.0 % | 7.0 % |
Financials
|
|||
5 yr Average ROE
|
12.21 % | 20.38 % | 15.79 % |
5yr average Equity Multiplier
|
2.48 | 1.34 | 1.48 |
5yr Average Asset Turnover Ratio
|
0.29 | 0.79 | 0.83 |
5yr Avg Net Profit Margin
|
15.17 % | 19.43 % | 13.0 % |
Price to Book
|
0.0 | 9.16 | 3.42 |
P/E
|
80.34 | 37.5 | 27.63 |
5yr Avg Cash Conversion Cycle
|
-69.14 Days | -93.41 Days | 1.45 Days |
Inventory Days
|
47.61 Days | 61.2 Days | 94.67 Days |
Days Receivable
|
114.09 Days | 52.69 Days | 60.69 Days |
Days Payable
|
279.35 Days | 198.04 Days | 176.63 Days |
5yr Average Interest Coverage Ratio
|
4.49 | 108.17 | 36.16 |
5yr Avg ROCE
|
10.49 % | 25.98 % | 17.34 % |
5yr Avg Operating Profit Margin
|
23.01 % | 27.51 % | 19.56 % |
5 yr average Debt to Equity
|
0.98 | 0.0 | 0.2 |
5yr CAGR Net Profit
|
99.71 % | 11.78 % | -5.77 % |
5yr Average Return on Assets
|
4.43 % | 15.32 % | 10.48 % |
Shareholdings
|
|||
Promoter Holding
|
45.77 % | 66.26 % | 69.61 % |
Share Pledged by Promoters
|
0.0 | 12.61 % | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.01 % | -4.22 % | 0.13 % |
Change in Mutual Fund Holding (3 Yrs)
|
-2.39 % | 4.63 % | 4.0 % |
Senores Pharmaceutic
|
Ajanta Pharma
|
Alembic Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|